Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
methotrexate + Iodine I 131 tositumomab
- Development stage
- Discontinued
- Lead developer
- GSK
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Beta-minus Emitters → Radiopharmaceuticals, Gamma Emitters → Radiopharmaceuticals, Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous, Oral
01
Overview
This combination therapy consists of low-dose methotrexate and the radioimmunotherapy Iodine I 131 tositumomab (Bexxar). It was specifically investigated by the University of Michigan Rogel Cancer Center for the treatment of previously untreated, advanced-stage follicular lymphoma. In this regimen, methotrexate, a small molecule antifolate, is used as an immunomodulatory agent to prevent the development of Human Anti-Mouse Antibodies (HAMA), which are common immune reactions against the murine-derived tositumomab protein. Iodine I 131 tositumomab targets the CD20 antigen on B-lymphocytes, allowing for the targeted delivery of ionizing radiation from the Iodine-131 isotope to malignant cells. The primary goal of adding methotrexate is to enhance the safety and potential for repeat dosing of the radioimmunotherapy by mitigating immunogenicity.
- Other names
- low-dose methotrexate and BexxarIodine I 131 tositumomab and methotrexate
02
Targets
CD20 (B-lymphocyte antigen CD20)DNADHFR (Dihydrofolate reductase)FcγR (Low affinity immunoglobulin gamma Fc region receptor II-c)
Beyond the preview
Go deeper on methotrexate + Iodine I 131 tositumomab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on methotrexate + Iodine I 131 tositumomab.